| pubmed-article:20636277 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0033607 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:20636277 | lifeskim:mentions | umls-concept:C0039725 | lld:lifeskim |
| pubmed-article:20636277 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:20636277 | pubmed:dateCreated | 2010-9-27 | lld:pubmed |
| pubmed-article:20636277 | pubmed:abstractText | Protease inhibitor (PI) resistance-associated mutations (RAMs) are commonly observed in PI-naïve patients who infected with HIV-1 subtype A/E. Few data are available on the genetic mechanisms of PI resistance in non-B HIV-1. This study was aimed to compare PI-RAMs between PI-naïve and -experienced patients and determine PI resistance in each group. Genotypic resistance testing was conducted among a cohort of HIV-1-infected patients who were diagnosed with virologic failure. We studied 137 patients of whom 75 patients were in PI-naïve group and 62 patients in PI-experienced group. Median CD4 cell count and HIV-1 RNA at virologic failure were 169 cells/mm³ and 14,100 copies/mL, respectively. The clinical characteristics between 2 groups were similar (p>0.05) except for the duration of antiretroviral therapy (ART) which was shorter in PI-naïve group (31.5 vs. 46.8 months, p=0.028). Proportion of patients with primary PI-RAMs was 2.7% in PI-naïve and 19% in PI-experienced groups (p=0.002). The most common primary PI-RAMs in the latter group were V82A (10%), I54V (7%) and G48V (4.8%). Proportion of patients with secondary PI-RAMs in the corresponding groups was 99% and 98%, respectively (p=1.000). The most common secondary PI-RAMs in both groups were M36I (91%), H69K (34%) and L89M (30%). In conclusion, primary PI-RAMs are observed exclusively among PI-experienced patients whereas secondary PI-RAMs are equally found in both PI-naïve and PI-experienced patients. Further studies to define virologic response of HIV-1 subtype A/E to various PIs and clinical validation of PI-RAMs in HIV-1 subtype A/E are essentially needed. | lld:pubmed |
| pubmed-article:20636277 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20636277 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20636277 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20636277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20636277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20636277 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20636277 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20636277 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20636277 | pubmed:issn | 1873-4251 | lld:pubmed |
| pubmed-article:20636277 | pubmed:author | pubmed-author:ChantratitaWa... | lld:pubmed |
| pubmed-article:20636277 | pubmed:author | pubmed-author:Sungkanuparph... | lld:pubmed |
| pubmed-article:20636277 | pubmed:author | pubmed-author:SukasemChonla... | lld:pubmed |
| pubmed-article:20636277 | pubmed:author | pubmed-author:Wiboonchutiku... | lld:pubmed |
| pubmed-article:20636277 | pubmed:author | pubmed-author:WathipthunCho... | lld:pubmed |
| pubmed-article:20636277 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20636277 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20636277 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:20636277 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20636277 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20636277 | pubmed:pagination | 456-60 | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:meshHeading | pubmed-meshheading:20636277... | lld:pubmed |
| pubmed-article:20636277 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20636277 | pubmed:articleTitle | Comparison of protease inhibitor (PI) resistance-associated mutations between PI-naïve and PI-experienced HIV-1 infected patients in Thailand where subtype A/E is predominant. | lld:pubmed |
| pubmed-article:20636277 | pubmed:affiliation | Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. | lld:pubmed |
| pubmed-article:20636277 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20636277 | pubmed:publicationType | Comparative Study | lld:pubmed |
